Nine-Month Figures: Sartorius Ltd. Grows in Double Digits
10/29/2012 6:45:40 AM
GOETTINGEN, Deutschland--(BUSINESS WIRE)--Sartorius, a leading international laboratory and pharmaceutical equipment provider, successfully closed the first nine months of 2012, with substantial gains in order intake, sales revenue and earnings. The Bioprocess Solutions Division that primarily specializes in single-use products for pharmaceutical drug manufacture performed especially well. In addition, initial consolidation of the Biohit Liquid Handling business substantially boosted growth for the Laboratory Products & Services Division. Based on the company’s strong business development in the first nine months, management slightly lifted its full-year guidance for its earnings yet again. Assuming that the currency exchange rates essentially remain favorable as in the first nine months of 2012, Sartorius expects adjusted earnings (operating EBITA) to increase by about 18% (former guidance: about 15%). Full-year guidance for sales remains unchanged: sales revenue is projected to grow by about 11% in constant currencies.